🇺🇸 FDA
Pipeline program

PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN

MK-3475-A86

Phase 3 small_molecule active

Quick answer

PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN for Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC). is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials